Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
Frontiers in oncology(2023)
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.979519.].
MoreTranslated text
Key words
endometrial cancer,immune response,lenvatinib,pembrolizumab,tyrosine kinase inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined